STTR Phase I: Protective T Cell Vaccine for SARS CoV-2 (COVID-19)

STTR 第一期：针对 SARS CoV-2 (COVID-19) 的保护性 T 细胞疫苗

• 批准号: 2131876
• 负责人: Lorraine Keller
• 金额: $ 25.6万
• 依托单位: MBF THERAPEUTICS, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2131876&HistoricalAwards=false
• 关键词: STTR; Phase; Protective; Cell; Vaccine

The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a fundamentally different next-generation SARS CoV-2 vaccine that addresses current gaps in efficacy, safety, and national and global distribution of vaccines. The rapid global emergence of the highly infectious delta variant underscores the importance of T cell immunity, increasingly recognized as critical to eliciting effective and long-term immunity to SARS CoV-2. An innovative DNA vaccine, delivered as a patient-friendly intranasal spray that does not require refrigeration, will improve public health. This Small Business Technology Transfer (STTR) Phase I project advances a multivalent SARS CoV-2 T cell vaccine by intranasal/pulmonary administration of calcium phosphate nanoparticle-formulated plasmids. Proteins comprising the SARS CoV-2 ORFeome will be cloned in proprietary plasmids (Aim 1) screened by in vitro challenge with PBMC from recovered donors (Aim 2) and safety/immunogenicity/challenge in vivo in hACE2 mice. The outcome of Phase I will be identification novel ORFs that elicit T cell responses in vivo and that in combination partially protective (50% survival at 14 days post infection) against challenge with SARS CoV-2.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业技术转让 (STTR) 第一阶段项目的更广泛影响/商业潜力是开发一种根本不同的下一代 SARS CoV-2 疫苗，以解决目前疫苗在功效、安全性以及国家和全球分配方面的差距。高传染性 delta 变体在全球的迅速出现凸显了 T 细胞免疫的重要性，人们越来越认识到 T 细胞免疫对于引发针对 SARS CoV-2 的有效和长期免疫至关重要。一种创新的 DNA 疫苗以患者友好的鼻内喷雾剂形式提供，无需冷藏，将改善公众健康。 该小企业技术转让 (STTR) 第一阶段项目通过鼻内/肺部施用磷酸钙纳米颗粒配制的质粒来开发多价 SARS CoV-2 T 细胞疫苗。 包含 SARS CoV-2 ORFeome 的蛋白质将被克隆到专有质粒（目标 1）中，通过使用来自康复供体的 PBMC 进行体外攻击（目标 2）以及 hACE2 小鼠体内的安全性/免疫原性/挑战进行筛选。第一阶段的结果将是鉴定新的 ORF，这些 ORF 能够在体内引发 T 细胞反应，并结合部分保护性（感染后 14 天存活率 50%）抵御 SARS CoV-2 的挑战。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力优点和更广泛的影响审查标准进行评估，被认为值得支持。